BNET Industries
Micrus Endovascular Corp. (MEND) is in the Health Care Industry
- Revenue
- Mar 31 2008
- $69.2M
- Profit
- Mar 31 2008
- ($16.2M)
- Market Cap
- Sep 04 2008
- $195.0M
Latest News and Analysis
Wallstrip: Micrus Endovascular Corp. (MEND)
Micrus Endovascular Corp. is in the business of prolonging life, and overseas markets appear to be just what the doctor ordered.
Micrus Endovascular Q4 2008, Earnings Call Transcript
Micrus Endovascular Q4 2008, Earnings Call Transcript
Additional Resources
Micrus Endovascular to Hold 2009 First Quarter Conference Call on August 7
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced that it will release financial results for the quarter ended June 30, 2008, on Thursday, August 7, 2008. Micrus' management will host an investment community conference call at 10:30 a.m. Eastern time (7:30 a.m. Pacific time) to discuss those results...
Micrus Endovascular Announces CE Mark for PHAROS Vitesse Stent
Next-Generation Stent Expands Product Offering in the Ischemic Market SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq: MEND) today announced that its PHAROS[TM] Vitesse[TM] intracranial stent has received CE Mark authorization for commercial distribution in the European Union and all countries recognizing the CE Mark....
Micrus Endovascular to Present at 7th Annual Needham & Company Biotechnology & Medical Technology Conference
SAN JOSE, Calif. -- Micrus Endovascular Corporation (NASDAQ: MEND) today announced that John Kilcoyne, Chairman and CEO, will present at the 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on Wednesday, June 11 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). ...
Positive Clinical Data Evaluating the Micrus Endovascular Cerecyte Microcoil Published in Peer-Reviewed Journals
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq: MEND) today announced that positive data from two clinical studies evaluating the use of the Micrus Endovascular Cerecyte[R] bioactive microcoil in the treatment of cerebral aneurysms have been published in peer-reviewed scientific journals. Cerecyte platinum microcoils contain a polyglycolic...
Wall Street Media Presents Exclusive Video Highlights from the 2008 FBR Capital Markets Conference
NEW YORK -- Wall Street Media is presenting three exclusive highlights from the presentations of Micrus Endovascular Corp., (Nasdaq: MEND), ev3, Inc., (Nasdaq: EVVV), and Life Sciences Research Inc., (NYSE: LSR), from the 2008 FBR Capital Markets Spring Investor Conference held on May 28-29, 2008 at the Grand Hyatt in...
Micrus Endovascular to Present at May Investment Conferences
SAN JOSE, Calif. -- Micrus Endovascular Corporation (NASDAQ:MEND) today announced that management will make presentations at three investment conferences in May: * Robert Stern, Micrus President and COO, will present at the Citigroup Healthcare Conference on Wednesday, May 21, at 8:00 a.m. Eastern time. The conference will be...
Micrus Endovascular Fourth Quarter Revenues Increase 23%
Provides Fiscal 2009 Revenue Guidance Conference Call Begins at 10:30 a.m. Eastern Time Today SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced financial results for the three months and fiscal year ended March 31, 2008, and provided fiscal 2009 revenue guidance. Micrus...
Micrus Endovascular to Hold 2008 Fourth Quarter and Full Year Conference Call on May 8
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq: MEND) today announced that it will release financial results for the quarter and fiscal year ended March 31, 2008, and introduce fiscal 2009 financial guidance before market open on Thursday, May 8, 2008. Micrus' management will host an investment community conference call...
Micrus Endovascular and Chemence Medical Products Sign Development Agreement for Liquid Embolic Products
SAN JOSE, Calif. & ALPHARETTA, Ga. -- Micrus Endovascular Corporation (Nasdaq:MEND) and privately held Chemence Medical Products, Inc. today announced the signing of an exclusive agreement to jointly develop liquid embolic products for neurovascular indications using Chemence's cyanoacrylate technology, development capabilities and intellectual property. Micrus Endovascular will be responsible for...
Zacks Analyst Interview Highlights: AtriCure, Micrus Endovascular and BioSphere Medical
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Tom Park, who discusses AtriCure, Inc. (Nasdaq: ATRC), Micrus Endovascular Corporation (Nasdaq: MEND) and BioSphere Medical, Inc. (Nasdaq: BSMD). A synopsis of today's Analyst Interview is presented below. The full article can be read...
Micrus Endovascular to Present at March Investment Conferences
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq: MEND) today announced that management will make presentations at four investment conferences in March: * Robert Stern, Micrus President and COO, will present at the Rodman & Renshaw "Straight to the Heart" one-day, one-on-one meeting conference on Tuesday, March 4....
Micrus Endovascular Reports 18% Third Quarter Revenue Growth
Conference Call Begins at 10:30 a.m. Eastern Time Today SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced financial results for the three and nine months ended December 31, 2007. Micrus reported revenues of $18.3 million for the third quarter of fiscal 2008, an increase...
Micrus Endovascular to Hold 2008 Third Quarter Conference Call on February 7
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq: MEND) today announced that it will release financial results for the quarter ended December 31, 2007 before market open on Thursday, February 7, 2008. Micrus' management will host an investment community conference call at 10:30 a.m. Eastern time (7:30 a.m. Pacific time)...
Micrus Endovascular and Genesis Medical Interventional Sign License, Development and Commercialization Agreement
SAN JOSE & REDWOOD CITY, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) and privately held Genesis Medical Interventional, Inc. today announced that they have entered into an agreement granting Micrus the rights to Genesis' F.A.S.T.[TM] Funnel Catheter[TM] and clot retrieval system for the treatment of ischemic stroke. The transaction includes an...
Micrus Endovascular to Present at 10th Annual Needham & Company Growth Conference
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced that Robert Stern, President and Chief Operating Officer, will present at the 10th Annual Needham & Company, LLC Growth Conference on Tuesday, January 8 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). A live...
Micrus Endovascular Receives Approval to Market Stretch-Resistant Microcoils in Japan
SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced receipt of Shonin approval from the Ministry of Health, Labour and Welfare MHLW to market in Japan its full line of stretch-resistant microcoils for the endovascular treatment of cerebral aneurysms, including the Cashmere[TM], Presidio[R], HeliPaq[R] and UltiPaq[R]...
Micrus Endovascular to Present at November Investment Conferences
Webcast Scheduled November 27 at 8:45 a.m. Eastern Time SAN JOSE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced that senior management will make presentations at three investment conferences in November: * Robert Stern, President and Chief Operating Officer, will present at the...
Micrus Endovascular Names Gordon Sangster Chief Financial Officer
SAN JOSE, Calif. -- Micrus Endovascular Corporation (NASDAQ:MEND) announces that Gordon Sangster has been named Chief Financial Officer, effective November 12, 2007. Mr. Sangster replaces Robert Stern, who has overseen the Company's financial operations since being promoted from Chief Financial Officer to President and Chief Operating Officer...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1996
- CEO: Mr. John T. Kilcoyne
Micrus Endovascular develops, manufactures and markets implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Co.'s products are used by interventional neuroradiologists, interventional neurologists and neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis which may lead to ischemic stroke. Co.'s product lines consist of endovascular systems that enable a physician to gain access to the brain in a minimally invasive manner through the vessels of the arterial.
Key Competitors
Micrus Endovascular Corp. Company Info
Board of Directors
Mr. John T. Kilcoyne
Chairman
Mr. Michael L. Eagle
Dr. Leo Nelson Hopkins M.D.
Mr. Fred Holubow
Mr. Francis J. Shammo
Mr. Jeffrey H. Thiel
Mr. Gregory H. Wolf
Contact Information
821 Fox Lane
San Jose, CA
408 433-1400